Eli Lilly and Company (BVMF:LILY34)

Market Cap	5.32T
Revenue (ttm)	316.67B
Net Income (ttm)	98.13B
Shares Out	n/a
EPS (ttm)	108.94
PE Ratio	54.25
Forward PE	34.35
Dividend	0.75 (0.38%)
Ex-Dividend Date	Nov 13, 2025

Volume	18,135
Average Volume	18,876
Open	199.10
Previous Close	198.61
Day's Range	196.32 - 202.00
52-Week Range	113.00 - 208.36
Beta	0.37
RSI	66.22
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD